AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

co.don AG

Regulatory Filings May 22, 2021

80_rns_2021-05-22_11ddd410-5d31-4490-9318-378b785d9e05.html

Regulatory Filings

Open in Viewer

Opens in native device viewer

Finanzbericht: 28261561

scrollen

Betreff: Ad-hoc-Meldung gemäß Art. 17 MAR in Verbindung mit § 4 Abs. 1 S. 1 Nr. 1a WpAV
Schlagworte: CO.DON AG /​ Product /​ Indication extension
Eintritt der Insiderinformationen: 22.05.2021
Ergänzende Angaben: CO.DON AG: EU-approved medicinal product receives vote for indication extension for use in adolescents

Angaben zum Inhalt:

scrollen

Inhalt der Ad-Hoc-Mitteilung: CO.DON AG: EU-approved medicinal product receives vote for indication extension for use in adolescents

Teltow (pta001/​22.05.2021/​00:01) - Teltow /​ Leipzig, 21 May 2021 - CO.DON AG (ISIN: DE000A1K0227) received today the positive vote of the CHMP (Committee for Medicinal Products for Human Use) of the EMA (European Medicines Agency) on the approval of the application for the indication extension of the EU-wide approved medicinal product for human use "Spherox - Spheroids from human autologous matrix-associated chondrocytes" for the use in adolescents.

The CHMP's assessment is the basis for the European Commission's decision on the EU-wide authorisation of the indication extension. In the past, the European Commission followed the recommendations of the CHMP in the vast majority of applications.

With the expanded indication for the EU, the treatment of symptomatic articular cartilage defects of ICRS Grade III or IV of the femoral condyle and the patella of the knee with defect sizes of up to 10 cm^2 is now also possible in adolescents with closed growth plates in addition to adult patients.

Notifying person: Tilman Bur, Management Board

Contact Matthias Meißner Director Corporate Communications Investor Relations /​ Public Relations T: +49 (0)341 99190 330 F: +49 (0)341 99190 309 E: [email protected]

emitter: CO.DON AG address: Warthestraße 21, 14513 Teltow country: Germany contact person: Matthias Meißner phone: +49 341 99190330 e-mail: [email protected] website: www.codon.de ISIN(s): DE000A1K0227 (share) stock exchanges: regulated market in Frankfurt; free market in Stuttgart, free market in Hamburg, free market in Dusseldorf; open market in Berlin, Tradegate source: http:/​/​adhoc.pressetext.com/​news/​1621634460297

Angaben zum Emittenten:

scrollen

Name: CO.DON AG
Adresse: Warthestraße 21, 14513 Teltow
E-Mail-Adresse: [email protected]
Internet-Adresse:: http:/​/​www.codon.de
ISIN: DE000A1K0227 (share)
Handelsplätze: regulated market in Frankfurt; free market in Stuttgart, free market in Hamburg, free market in Dusseldorf; open market in Berlin, Tradegate

Angaben zur Pflichtmitteilung:

scrollen

Veröffentlichung in elektronisch betriebenen Informationsverbreitungssystem: pressetext.adhoc, published over Bloomberg, Dow Jones Newswires and Thomson Reuters
Pflichtveröffentlichung am: 22.05.2021
Uhrzeit der Veröffentlichung: 00:01:00
Pflichtveröffentlichung in/​über: pressetext.adhoc, published over Bloomberg, Dow Jones Newswires and Thomson Reuters
Pflichtveröffentlichung am: 2021-05-22
Sprachen der Veröffentlichung: Englisch

Talk to a Data Expert

Have a question? We'll get back to you promptly.